MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is an open label trial to assess the efficacy of MBM-02 (Tempol) as a treatment for
patients diagnosed with prostate cancer in biochemical recurrence.